Glial cell response: A pathogenic factor in Parkinson's disease

被引:26
|
作者
Wu, DC
Tieu, K
Cohen, O
Choi, DK
Vila, M
Jackson-Lewis, V
Teismann, P
Przedborski, S
机构
[1] Columbia Univ, Dept Neurol, Movement Disorder Div, New York, NY 10032 USA
[2] Columbia Univ, Dept Pathol, New York, NY USA
关键词
astrocyte; gliosis; IL-1; beta; iNOS; microglia; MPTP; neurodegeneration; Parkinson's disease;
D O I
10.1080/13550280290100905
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The loss of these neurons is associated with a glial response composed mainly of activated microglial cells and, to a lesser extent, of reactive astrocytes. This glial response may be the source of trophic factors and can protect against reactive oxygen species and glutamate. Alternatively, this glial response can also mediate a variety of deleterious events related to the production of pro-oxidant reactive species, proinflammatory prostaglandin, and cytokines. In this review, the authors discuss the potential protective and deleterious effects of glial cells in the SNpc of PD and examine how these factors; may contribute to the pathogenesis of this disease.
引用
收藏
页码:551 / 558
页数:8
相关论文
共 50 条
  • [21] Glial neurotrophiz factor as a differential marker of Parkinson`s disease and vascular parkinsonism
    Matmurodov, R.
    Abduqodirov, E.
    Juraev, R.
    Naimov, O.
    Muminov, B.
    Khalimova, K.
    Daminova, H.
    MOVEMENT DISORDERS, 2023, 38 : S120 - S120
  • [23] In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease - Discussion
    Isacson
    Kordower
    Brooks
    Olanow
    Hunot
    Stocchi
    Jenner
    Rascol
    Marek
    ANNALS OF NEUROLOGY, 2003, 53 : S132 - S134
  • [25] Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease
    Grondin, R
    Gash, DM
    JOURNAL OF NEUROLOGY, 1998, 245 (Suppl 3) : P35 - P42
  • [26] Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease
    Whone, Alan
    Luz, Matthias
    Boca, Mihaela
    Woolley, Max
    Mooney, Lucy
    Dharia, Sonali
    Broadfoot, Jack
    Cronin, David
    Schroers, Christian
    Barua, Neil U.
    Longpre, Lara
    Barclay, C. Lynn
    Boiko, Chris
    Johnson, Greg A.
    Fibiger, H. Christian
    Harrison, Rob
    Lewis, Owen
    Pritchard, Gemma
    Howell, Mike
    Irving, Charlie
    Johnson, David
    Kinch, Suk
    Marshall, Christopher
    Lawrence, Andrew D.
    Blinder, Stephan
    Sossi, Vesna
    Stoessl, A. Jon
    Skinner, Paul
    Mohr, Erich
    Gill, Steven S.
    BRAIN, 2019, 142 : 512 - 525
  • [27] Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease
    Cunningham, LA
    Su, C
    EXPERIMENTAL NEUROLOGY, 2002, 174 (02) : 230 - 242
  • [28] Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson’s disease
    R. Grondin
    Don M. Gash
    Journal of Neurology, 1998, 245 : P35 - P42
  • [29] Glial cell line derived neurotrophic factor gene delivery in rat models of Parkinson's disease.
    Bohn, MC
    Connor, B
    Kozlowski, DA
    JOURNAL OF NEUROCHEMISTRY, 2000, 74 : S40 - S40
  • [30] Immune response mediators as a factor of Parkinson's disease
    Muinjonov, Bakhrom
    Giyazitdinova, Elvina
    Musayeva, Yulduz
    Rakhmibayeva, Gulnora
    MOVEMENT DISORDERS, 2016, 31 : S20 - S20